Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma

Histopathology

Volumn 64, Issue 7, 2014, Pages 935-950

  Chan, Anthony W H ^a   Tong, Joanna H M ^a,b   Chan, Stephen L ^a   Lai, Paul B S ^b   To, Ka Fai ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

AJCC TNM stage; CD133; EpCAM; Hepatocellular carcinoma; Stemness marker

Indexed keywords

CD133 ANTIGEN; CD56 ANTIGEN; CYTOKERATIN 19; EPITHELIAL CELL ADHESION MOLECULE; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR VOLUME; AGED; COHORT ANALYSIS; GENE EXPRESSION REGULATION; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899978058     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12342     Document Type: Article

References (24)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0. Cancer incidence and mortality worldwide. IARC CancerBase no. 10 (internet). Lyon, France: International Agency for Research on Cancer, http://globocan.iarc.fr.
2. Vauthey JN, Lauwers GY, Esnaola NF et al. Simplified staging for hepatocellular carcinoma. J. Clin. Oncol. 2002; 20; 1527-1536.
3. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res. 2006; 66; 1883-1890; discussion 1895-1886.
4. Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin. Oncol. 2012; 39; 461-472.
5. Theise ND, Nakashima O, Park YN, Nakanuma Y. Combined hepatocellular - cholangiocarcinoma. In Bosman FT, Carneiro F, Hruban RH, Theise ND eds. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer, 2010; 225-227.
6. Bae JS, Noh SJ, Jang KY et al. Expression and role of epithelial cell adhesion molecule in dysplastic nodule and hepatocellular carcinoma. Int. J. Oncol. 2012; 41; 2150-2158.
7. Kim H, Choi GH, Na DC et al. Human hepatocellular carcinomas with 'stemness'-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 2011; 54; 1707-1717.
8. Yang XR, Xu Y, Yu B et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010; 59; 953-962.
9. Theise ND, Curado MP, Franceshi S et al. Hepatocellular carcinoma. In Bosman FT, Carneiro F, Hruban RH, Theise ND eds. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer, 2010; 205-216.
10. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem. Biophys. Res. Commun. 2006; 351; 820-824.
11. Lingala S, Cui YY, Chen X et al. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp. Mol. Pathol. 2010; 89; 27-35.
12. Sasaki A, Kamiyama T, Yokoo H et al. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol. Rep. 2010; 24; 537-546.
13. Tsuchiya A, Kamimura H, Takamura M et al. Clinicopathological analysis of CD133 and NCAM human hepatic stem/progenitor cells in damaged livers and hepatocellular carcinomas. Hepatol. Res. 2009; 39; 1080-1090.
14. Yeh CT, Kuo CJ, Lai MW et al. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer 2009; 9; 324.
15. Zen C, Zen Y, Mitry RR et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl. 2011; 17; 943-954.
16. Song W, Li H, Tao K et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int. J. Clin. Pract. 2008; 62; 1212-1218.
17. Schmelzer E, Wauthier E, Reid LM. The phenotypes of pluripotent human hepatic progenitors. Stem Cells 2006; 24; 1852-1858.
18. Shan YF, Huang YL, Xie YK et al. Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and alpha-fetoprotein expression status. Med. Oncol. 2011; 28; 1012-1016.
19. Yamashita T, Forgues M, Wang W et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008; 68; 1451-1461.
20. Schulze K, Gasch C, Staufer K et al. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int. J. Cancer 2013; 133; 2165-2171.
21. Sun YF, Xu Y, Yang XR et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013; 57; 1458-1468.
22. Tsuchiya A, Kamimura H, Tamura Y et al. Hepatocellular carcinoma with progenitor cell features distinguishable by the hepatic stem/progenitor cell marker NCAM. Cancer Lett. 2011; 309; 95-103.
23. Uenishi T, Kubo S, Yamamoto T et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003; 94; 851-857.
24. Simon M, Stefan N, Pluckthun A, Zangemeister-Wittke U. Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert Opin. Drug Deliv. 2013; 10; 451-468.